Abstract: This invention is directed to His-tag binding compounds and uses thereof in the preparation of genetically targeted detectable molecules and sensors which can specifically bind tag-labeled proteins. This invention further provides a system comprising recombinant cells decorated with various labels and/or synthetic agents, wherein said labels and/or synthetic agents can be reversibly modified or removed from the cells. Also disclosed herein are methods for decorating and/or modifying the cells and methods for using thereof.
Type:
Grant
Filed:
February 6, 2020
Date of Patent:
May 2, 2023
Assignee:
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Inventors:
David Margulies, Leila Motiei, Naama Lahav
Abstract: Embodiments pertain to ureteral stents for treatment of partial or full ureteral occlusion by bridging one or more ureteral occlusions, where each stent includes a tubular portion, a first spout portion and a second spout portion. The stent may have one or more tapered edges by having the smallest diameter of the first and/or the second spout portion smaller than the largest diameter of the tubular portion, and/or be of an overall length allowing the ureteral stent to be completely located within a patient's ureter once deployed therein.
Type:
Application
Filed:
March 18, 2021
Publication date:
April 27, 2023
Applicants:
Mor Research Applications Ltd., Yeda Research and Development Co. Ltd.
Abstract: Disclosed herein are anti-CTLA-4 antibodies possessing superior binding and biological activities relative to ipibmumab and tremelimumab, pharmaceutical compositions comprising such. Also provided herein are therapeutic and diagnostic applications of such anti-CTLA-4 antibodies.
Type:
Application
Filed:
September 20, 2019
Publication date:
April 27, 2023
Applicants:
Tikcro Technologies Ltd., Yeda Research and Development Co. Ltd.
Abstract: A method of reducing a friction coefficient of a surface is disclosed herein, comprising attaching a water-soluble polymer to the surface, and contacting the water-soluble polymer with liposomes, thereby coating the surface with an amphiphilic lipid. Further disclosed herein are solutions comprising a water-soluble polymer attachable to the surface, liposomes, and an aqueous carrier, for reducing a friction coefficient of a surface, and methods utilizing same. Articles of manufacture comprising a substrate coated by a water-soluble polymer which is coated by an amphiphilic lipid are also described, as are uses and methods for treating a synovial joint disorder associated with increased articular friction.
Abstract: Described herein are anti-human Grp94 antibodies. The antibodies may be used to target senescent cells. Thus, the anti-Grp94 antibodies would be useful in treating diseases and conditions associated with cellular senescence. The anti-Grp94 antibodies could target senescent cells in vivo. Therefore, the anti-Grp94 antibodies could be used to target senescent cells associated with age-related diseases in vivo.
Abstract: Method of predicting a response of a subject to food is disclosed. The method comprises: selecting a food to which a response of the subject is unknown; accessing a first database having data describing the subject but not a response of the subject to the selected food; accessing a second database having data pertaining to responses of other subjects to foods, the responses of the other subjects including responses of at least one other subject to the selected food or a food similar to said selected food; and analyzing the databases based on the selected food to estimate the response of the subject to the selected food.
Abstract: The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction.
Type:
Application
Filed:
November 10, 2022
Publication date:
March 16, 2023
Applicants:
YEDA RESEARCH AND DEVELOPMENT CO., LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LT
Inventors:
Jacob KLEIN et al., Ronit Goldberg, Yechezkel Barenholtz, Avi Schroeder
Abstract: A method of identifying a molecular composition and a spatial position of a single cell comprised in a 3 dimensional structure comprising a plurality of cells is provided.
Type:
Application
Filed:
November 21, 2022
Publication date:
March 16, 2023
Applicant:
Yeda Research and Development Co. Ltd.
Inventors:
Amos TANAY, Elad CHOMSKY, Yonatan STELZER, Raz BEN-YAIR
Abstract: Disclosed herein are 3, 4-didehydro- and 3?-deoxy-3, 4-didehydro-compounds and pharmaceutical compositions thereof. Methods of use of these pharmaceutical compositions include those for treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SAR-CoV-2, EBV, BKV, JCV and HCMV.
Type:
Application
Filed:
January 25, 2022
Publication date:
March 9, 2023
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO. LTD
Inventors:
Helena SHOMAR MONGES, Rotem SOREK, Lianet NODA GARCIA, Arthur MACHLENKIN, David SPERANDIO
Abstract: A method of predicting an analyte level comprises receiving a time-ordered series of levels of the analyte, monitored over a time-period; feeding a trained neural network procedure with the monitored levels; and displaying, based on an output received from the procedure, a predicted level of the analyte in a future time. The procedure can comprise a plurality of layers, wherein for at least one pair of layers, a number of inter-layer connections within the pair is higher for later monitored levels than for earlier monitored levels.
Type:
Application
Filed:
February 17, 2020
Publication date:
March 9, 2023
Applicants:
Yeda Research and Development Co. Ltd., Mor Research Applications Ltd.
Abstract: A prosodic speech recognition engine configured to identify prosodic features and patterns in a speech continuum for the extraction of linguistic content including para-syntactic content, discourse function, information structure, meaning, and speaker sentiment.
Abstract: An article of manufacture is provided. The article of manufacture comprising a first binding moiety which specifically binds a human FcgamaRIIB and blocks interaction with IgG antibodies and a second binding moiety which specifically binds a human PD-L1, wherein the second binding moiety which specifically binds the human PD-L1 is an antibody of a human IgG1 isotype.
Abstract: A downloadable navigator for a mobile ultrasound unit having an ultrasound probe, implemented on a portable computing device. The navigator includes a trained orientation neural network to receive a non-canonical image of a body part from the mobile ultrasound unit and to generate a transformation associated with the non-canonical image, the transformation transforming from a position and rotation associated with a canonical image to a position and rotation associated with the non-canonical image; and a result converter to convert the transformation into orientation instructions for a user of the probe and to provide and display the orientation instructions to the user to change the position and rotation of the probe.
Type:
Grant
Filed:
May 15, 2019
Date of Patent:
February 28, 2023
Assignees:
New York University, Yeda Research And Development Co. Ltd
Abstract: A device for controlling respiration during sleep based on the user physiological characteristic. The device includes an odor disperser for dispersing an odor; at least one detector for detecting a physiological characteristic of a user; and a controller for controlling respiration of the user by instructing the odor dispenser to disperse an odor responsive to detections by the at least one detector.
Type:
Application
Filed:
October 28, 2022
Publication date:
February 23, 2023
Applicant:
Yeda Research and Development Co. Ltd.
Inventors:
Anat ARZI, Lee SELA, Anton PLOTKIN, Aharon WEISSBROD, Noam SOBEL
Abstract: Assays and methods for diagnosing and treating autoimmune diseases. Particularly, the invention provides methods for differential diagnosis of specific autoimmune diseases, including autoimmune rheumatic disorders.
Type:
Application
Filed:
September 29, 2022
Publication date:
February 16, 2023
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Inventors:
Rachel SOREK, Keren JAKOBI-BROOK, Pennina SAFER, Irun R. COHEN
Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The method comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoietic cells, wherein the T cell depleted immature hematopoietic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject; and subsequently (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per kilogram body weight, thereby treating the subject.
Abstract: A reflective optical system (100) comprising at least one reflective aspheric surface (1) of focal length f0 and optical axis (Z), the surface being configured so that an incident laser beam (2) propagating along an axis (Z?) is focused along the optical axis (Z) with a FWHM ((Full Width at Half Maximum) of the intensity of the reflected beam along the optical axis (Z) being larger, preferably by a factor of at least 10, than the FWHM of the intensity of a focused beam reflected by a parabola having same focal length f0 and same optical axis (Z), receiving same beam.
Type:
Grant
Filed:
June 24, 2019
Date of Patent:
February 7, 2023
Assignees:
Ecole Polytechnique, Ecole Nationale Supérieure de Techniques Avancées, Centre National de La Recherche Scientifique, Yeda Research and Development Co. Ltd.
Abstract: Disclosed herein are genetically modified plants expressing multiple animal milk proteins. Further disclosed are vectors for expressing in a plant and parts thereof, multiple mammalian milk proteins; genetically modified and or gene-edited plants having at least one cell expressing and producing at least two recombinant mammalian milk proteins wherein expression may be in a seed, bean, grain, fruit, nut, legume, leaf, stem, root, or portion thereof, the recombinant protein being produced by the plant cell; and a method of producing a food, medicament, cosmetic or blocking composition from the genetically modified or gene-edited plant. Reduction or elimination of seed storage proteins in a cell or cells wherein the milk proteins are expressed, or reduction of plant enzymes that can increase the content of oleic and/or stearic fatty acids and/or reduce the content of saturated fats in the plants or plant products are also disclosed.
Abstract: A method of generating an isolated population of cells comprising anti-third party cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance-inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) contacting peripheral blood mononuclear cells (PBMC) with a third party antigen or antigens in the presence of IL-21 so as to allow enrichment of antigen reactive cells; and (b) culturing the cells resulting from step (a) in the presence of IL-21, IL-15 and IL-7 in an antigen free environment so as to allow proliferation of cells comprising the central memory T-lymphocyte (Tcm) phenotype.
Type:
Application
Filed:
May 3, 2022
Publication date:
January 26, 2023
Applicant:
Yeda Research and Development Co. Ltd.
Inventors:
Yair REISNER, Yaki EIDELSTEIN, Eran OPHIR, Assaf LASK, Ran AFIK, Noga OR-GEVA, Esther BACHAR-LUSTIG
Abstract: An isolated cytotoxic T-lymphocyte (CTL), said CTL being a tolerance inducing cell and substantially depleted of alloreactivity, and wherein said CTL does not comprise a central memory T-lymphocyte (Tcm) phenotype, the CTL being transduced to express a cell surface receptor comprising a T cell receptor signaling module, is disclosed. Methods of generating same and using same are also disclosed.